Stay updated on Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.3%
    Check dated 2025-08-10T00:34:25.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    4%
    Check dated 2025-08-01T18:53:01.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.
    Difference
    0.8%
    Check dated 2025-07-25T13:52:29.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.3%
    Check dated 2025-07-18T10:50:25.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    4%
    Check dated 2025-07-11T06:58:18.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.
    Difference
    5%
    Check dated 2025-07-04T01:19:43.000Z thumbnail image

Stay in the know with updates to Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.